The Alzheimer’s Drug Discovery Foundation (ADDF)’s Diagnostics Accelerator (DxA) today announced a $10M investment in Alamar Biosciences, Inc. This landmark investment, the largest in DxA history, ...
NEW YORK, June 2, 2025 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) today announced an investment of up to $2M to expand a quality control program for blood and CSF biomarkers, ...
New investment supports DxA's mission to advance the development of scalable and universally accessible diagnostics. Blood tests will be key to further evolving Alzheimer's diagnostics, care, and ...
NEW YORK, Nov. 14, 2024 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF)'s Diagnostics Accelerator today announced a $1.18M investment in the University of Gothenburg (Sweden) to ...
Siemens is the first of many partners to non-exclusively license SpeechDx's speech and clinical dataset with the goal of developing a speech-based biomarker for Alzheimer's disease. NEW YORK, May 1, ...
NEW YORK and FREMONT, Calif., Jan. 8, 2025 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF)'s Diagnostics Accelerator (DxA) today announced a $10M investment in Alamar Biosciences, Inc ...
NEW YORK, June 2, 2025 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) today announced an investment of up to $2M to expand a quality control program for blood and CSF biomarkers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results